Today, Noubar Afayan, founder of Flagship Pioneering, published the venture capital firm’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.
Earlier this week, a Flagship-backed company, Generate Bio, inked an almost $2 billion deal for protein therapeutics with Amgen. That deal is just one example of Flagship’s success in identifying and helping launch and invest in life science companies.
